Renal, hepatic and cardiac function in healthy dogs during long-term celecoxib therapy/Funcao renal, hepatica e cardiaca de caes higidos sob terapia prolongada com celecoxibe

The aim of this study was to evaluate the effects of long-term celecoxib therapy on renal, hepatic and cardiac profiles in healthy dogs. Twelve female were randomly assigned to 2 groups ((G): Gcelecoxib: treated with celecoxib orally (5mg [kg.sup.-1]), every 12 hours, for 20 days (8.9 [+ or -] 1.6 body weight); Gcontrol: received placebo orally, every 12 hours, for 20 days (9.8 [+ or -] 1.8 body weight). Physical examination, renal function (urinalysis, urinary sodium and gamma-glutamyl transpeptidase -GGT), serum urea, creatinine, potassium and sodium, and endogenous creatinine clearance), clotting time (CT), cardiac biomarkers (creatine phosphokinase -CK and CK-MB) and liver function (aspartate aminotransferase -AST, alanine aminotransferase--ALT and albumin) were evaluated before, at 5, 10 and 20 days (T0, T5, T10 and T20) of treatment. The creatinine clearance values showed significant decrease at T20, in relation to T0 and T5 in the Gcelecoxib, and reduction in relation to Gcontrol at T10 and T20. The urinalysis, values of sodium, potassium, urea and creatinine serum and urinary GGT enzyme showed no difference through the study between moments or groups. There was a significant increase on CK values at T20 and on ALT values at T5, T10 and T20 in the Gcelecoxib, however with normal range values for dogs. Celecoxib revealed to be safe in relation to cardiac and hepatic profiles, even under prolonged therapy. However, it should be used judiciously during long-term therapy in dogs with renal dysfunction. Key words: celecoxib, dogs, renal function, hepatic function, cardiac biomarkers. O presente estudo teve como objetivo avaliar os efeitos da terapia prolongada com celecoxibe sobre a funcao renal, hepatica e cardiaca em caes higidos. Foram utilizados 12 caes femeas, divididos em 2 grupos: Gcelecoxibe: terapia com celecoxibe, na dose de 5mg [kg.sup.-1] por via oral, a cada 12 horas, durante 20 dias (peso medio de 8,9 [+ or -] 1,6); Gcontrole: terapia com placebo, a cada 12 horas, por via oral, 20 dias (peso medio de 9,8 [+ or -] 1,8). O exame fisico, a funcao renal (urinalise; gamaglutamil transpeptidase -GGT e sodio urinarios; ureia, creatinina, sodio e potassio sericos; e clearance endogeno de creatinina), tempo de coagulacao (TC), biomarcadores cardiacos (creatinofosfoquinase -CK e creatinofosfoquinase fracao MB- CK-MB) e funcao hepatica (alanina aminotransferase -.ALT, aspartato aminotransferase -AST e albumina) foram avaliados antes, aos 5, 10 e 20 di